MX9802383A - Derivados de pirimidina como antagonistas del receptor 5ht26. - Google Patents
Derivados de pirimidina como antagonistas del receptor 5ht26.Info
- Publication number
- MX9802383A MX9802383A MX9802383A MX9802383A MX9802383A MX 9802383 A MX9802383 A MX 9802383A MX 9802383 A MX9802383 A MX 9802383A MX 9802383 A MX9802383 A MX 9802383A MX 9802383 A MX9802383 A MX 9802383A
- Authority
- MX
- Mexico
- Prior art keywords
- 5ht2c
- pyrimidine derivatives
- receptor antagonists
- derivatives
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los derivados descritos de la pirimidina y las sales farmacéuticamente aceptables de los mismos, muestran propiedades farmacologicas utiles en el uso particular de antagonistas del receptor 5HT2C. La invencion también se dirige a formulaciones de tratamiento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US473395P | 1995-10-02 | 1995-10-02 | |
PCT/EP1996/004099 WO1997012880A1 (en) | 1995-10-02 | 1996-09-19 | Pyrimidine derivatives as 5ht2c-receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9802383A true MX9802383A (es) | 1998-08-30 |
Family
ID=21712250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9802383A MX9802383A (es) | 1995-10-02 | 1996-09-19 | Derivados de pirimidina como antagonistas del receptor 5ht26. |
Country Status (23)
Country | Link |
---|---|
US (1) | US5753663A (es) |
EP (1) | EP0856001B1 (es) |
JP (1) | JP3071830B2 (es) |
KR (1) | KR100258052B1 (es) |
CN (1) | CN1118460C (es) |
AR (1) | AR004516A1 (es) |
AT (1) | ATE222892T1 (es) |
AU (1) | AU700637B2 (es) |
BR (1) | BR9610823A (es) |
CA (1) | CA2233003A1 (es) |
CZ (1) | CZ98998A3 (es) |
DE (1) | DE69623306T2 (es) |
DK (1) | DK0856001T3 (es) |
EA (1) | EA001311B1 (es) |
ES (1) | ES2180798T3 (es) |
HU (1) | HUP9802323A3 (es) |
IL (1) | IL123581A (es) |
MX (1) | MX9802383A (es) |
NO (1) | NO310072B1 (es) |
NZ (1) | NZ319158A (es) |
PL (1) | PL326083A1 (es) |
PT (1) | PT856001E (es) |
WO (1) | WO1997012880A1 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9222253D0 (en) * | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
GB9304919D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
GB9304920D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
US6245774B1 (en) | 1994-06-21 | 2001-06-12 | Celltech Therapeutics Limited | Tri-substituted phenyl or pyridine derivatives |
US5786354A (en) * | 1994-06-21 | 1998-07-28 | Celltech Therapeutics, Limited | Tri-substituted phenyl derivatives and processes for their preparation |
GB9412571D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
GB9412573D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
CA2218503C (en) * | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
GB9622363D0 (en) * | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
US6057329A (en) * | 1996-12-23 | 2000-05-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives |
GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
GB9713087D0 (en) * | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9924862D0 (en) * | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
WO2001087845A2 (en) * | 2000-05-15 | 2001-11-22 | Fujisawa Pharmaceutical Co., Ltd. | N-containing heterocyclic compounds and their use as 5-ht antagonists |
PL367130A1 (en) * | 2001-05-29 | 2005-02-21 | Schering Aktiengesellschaft | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
MXPA06002608A (es) | 2002-12-20 | 2007-01-23 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento del crecimiento celular anormal. |
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
CA2564199A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
US20060205945A1 (en) * | 2004-05-14 | 2006-09-14 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
EP1756090A1 (en) | 2004-05-14 | 2007-02-28 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
EP1751142A1 (en) | 2004-05-14 | 2007-02-14 | Pfizer Products Incorporated | Pyrimidines derivatives for the treatment of abnormal cell growth |
AU2006224636A1 (en) * | 2005-03-15 | 2006-09-21 | F. Hoffmann-La Roche Ag | Use of 2 -anilino - 3 , 4 -dihydro - quinazolines as 5HT5A receptor antagonists |
WO2009081222A1 (en) | 2007-12-21 | 2009-07-02 | Glenmark Pharmaceuticals, S.A. | Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands |
BRPI0921924A2 (pt) | 2008-11-20 | 2015-12-29 | Merck Sharp & Dohme | composto, composição farmacêutica, uso de uma composição farmacêutica, e de um composto, e, método de tratamento de uma doença ou distúrbio mediado pelo receptor m1 muscarínico |
BRPI0923786C8 (pt) * | 2008-12-30 | 2021-05-25 | Arqule Inc | compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos |
EP2512245B1 (en) * | 2009-12-14 | 2014-07-23 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone m1 receptor positive allosteric modulators |
WO2011084371A1 (en) * | 2009-12-21 | 2011-07-14 | Merck Sharp & Dohme Corp. | Aminobenzoquinazolinone m1 receptor positive allosteric modulators |
TWI402264B (zh) * | 2010-05-12 | 2013-07-21 | Merck Sharp & Dohme | 芳基甲基苯并喹唑啉酮m1受體之正向異位性調節劑 |
US8735386B2 (en) * | 2010-07-23 | 2014-05-27 | Boehringer Ingelheim International Gmbh | Aminopyrazoloquinazolines |
CN110151745A (zh) | 2011-12-13 | 2019-08-23 | Io治疗公司 | 使用rxr激动剂的自身免疫紊乱的治疗 |
CN103214489B (zh) * | 2013-02-25 | 2016-10-26 | 中国人民解放军第二军医大学 | 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3177216A (en) * | 1961-12-28 | 1965-04-06 | Searle & Co | 4-trifluoromethyl-2-thio-5h-alka[d]-pyrimidines and congeners |
US3257400A (en) * | 1964-06-10 | 1966-06-21 | Searle & Co | 2-amino-5, 6-dihydrobenzo[h]quinazolin-4(3h)-one and congeners |
US3925384A (en) * | 1974-10-21 | 1975-12-09 | Squibb & Sons Inc | 2-Amino-4,5-dihydro-4-arylindeno pyrimidines |
IL103502A0 (en) * | 1991-10-24 | 1993-03-15 | Merck Sharp & Dohme | Benzodiazepine derivatives,their preparation and pharmaceutical compositions containing them |
-
1996
- 1996-09-19 WO PCT/EP1996/004099 patent/WO1997012880A1/en not_active Application Discontinuation
- 1996-09-19 CN CN96197385A patent/CN1118460C/zh not_active Expired - Fee Related
- 1996-09-19 AU AU71311/96A patent/AU700637B2/en not_active Ceased
- 1996-09-19 EP EP96932569A patent/EP0856001B1/en not_active Expired - Lifetime
- 1996-09-19 HU HU9802323A patent/HUP9802323A3/hu unknown
- 1996-09-19 CZ CZ98989A patent/CZ98998A3/cs unknown
- 1996-09-19 ES ES96932569T patent/ES2180798T3/es not_active Expired - Lifetime
- 1996-09-19 AT AT96932569T patent/ATE222892T1/de not_active IP Right Cessation
- 1996-09-19 NZ NZ319158A patent/NZ319158A/en unknown
- 1996-09-19 DE DE69623306T patent/DE69623306T2/de not_active Expired - Fee Related
- 1996-09-19 JP JP9513926A patent/JP3071830B2/ja not_active Expired - Fee Related
- 1996-09-19 CA CA002233003A patent/CA2233003A1/en not_active Abandoned
- 1996-09-19 BR BR9610823A patent/BR9610823A/pt not_active IP Right Cessation
- 1996-09-19 EA EA199800340A patent/EA001311B1/ru not_active IP Right Cessation
- 1996-09-19 IL IL12358196A patent/IL123581A/en not_active IP Right Cessation
- 1996-09-19 MX MX9802383A patent/MX9802383A/es not_active IP Right Cessation
- 1996-09-19 KR KR1019980702391A patent/KR100258052B1/ko not_active IP Right Cessation
- 1996-09-19 DK DK96932569T patent/DK0856001T3/da active
- 1996-09-19 PL PL96326083A patent/PL326083A1/xx unknown
- 1996-09-19 PT PT96932569T patent/PT856001E/pt unknown
- 1996-09-24 US US08/719,062 patent/US5753663A/en not_active Expired - Fee Related
- 1996-10-01 AR ARP960104557A patent/AR004516A1/es unknown
-
1998
- 1998-04-01 NO NO981477A patent/NO310072B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
KR19990063918A (ko) | 1999-07-26 |
PT856001E (pt) | 2003-01-31 |
HUP9802323A2 (hu) | 1999-03-29 |
IL123581A0 (en) | 1998-10-30 |
IL123581A (en) | 2001-09-13 |
US5753663A (en) | 1998-05-19 |
AR004516A1 (es) | 1998-12-16 |
ATE222892T1 (de) | 2002-09-15 |
NO981477L (no) | 1998-06-02 |
CA2233003A1 (en) | 1997-04-10 |
DE69623306D1 (de) | 2002-10-02 |
AU700637B2 (en) | 1999-01-07 |
HUP9802323A3 (en) | 1999-08-30 |
KR100258052B1 (ko) | 2000-08-01 |
DE69623306T2 (de) | 2003-04-17 |
AU7131196A (en) | 1997-04-28 |
JP3071830B2 (ja) | 2000-07-31 |
EP0856001B1 (en) | 2002-08-28 |
CZ98998A3 (cs) | 1998-10-14 |
CN1118460C (zh) | 2003-08-20 |
NO310072B1 (no) | 2001-05-14 |
JPH10512288A (ja) | 1998-11-24 |
CN1198743A (zh) | 1998-11-11 |
NO981477D0 (no) | 1998-04-01 |
NZ319158A (en) | 1999-10-28 |
ES2180798T3 (es) | 2003-02-16 |
EA001311B1 (ru) | 2001-02-26 |
BR9610823A (pt) | 1999-07-13 |
PL326083A1 (en) | 1998-08-17 |
EA199800340A1 (ru) | 1998-10-29 |
DK0856001T3 (da) | 2002-12-30 |
EP0856001A1 (en) | 1998-08-05 |
WO1997012880A1 (en) | 1997-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9802383A (es) | Derivados de pirimidina como antagonistas del receptor 5ht26. | |
ZA962522B (en) | Quinazoline derivatives. | |
HK1018788A1 (en) | Antivirally active heterocyclic azahexane derivatives. | |
AU6878894A (en) | 1-benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives | |
ZA9811339B (en) | Benzamidine derivatives. | |
ZA986905B (en) | Substituted quinazoline derivatives. | |
AU5130299A (en) | Wrist-mounted i.v. administration set | |
HUP9602745A3 (en) | Anticelladhesive piperidine- und pyrrolidine-carbonacids, pharm | |
HRP980398B1 (en) | 5H-THIAZOLO /3,2-a/ PYRIMIDINE DERIVATIVES | |
AU5835098A (en) | Use of pyrimidine derivatives for the prevention of cancer, on their own or in combination with other therapeutic measures | |
GR3036669T3 (en) | O-carbamoyl-phenylalaninol having substituent at benzene ring, its pharmaceutically useful salts and method for preparing the same | |
ZA985121B (en) | 3-Substituted 3,4-dihyrothieno(2,3-d)pyrimidine derivatives their preparation and use. | |
EP0840606A4 (es) | ||
HK1010196A1 (en) | Novel 2,3-dioxo-1,2,3,4-tetrahdro-quinoyxalinyl derivatives. | |
ZA978045B (en) | New benzamidine derivatives. | |
ZA961697B (en) | Indole derivatives. | |
AU8885498A (en) | Triazine derivatives, their production and use | |
AU2894297A (en) | 2,4-diaminopyrimidine derivatives | |
AU3819200A (en) | 2,4-diamino-pyrimidine derivatives | |
ZA972328B (en) | Fluoroalkyl- and fluoroalkoxy-substituted heterocyclic bradykinin antagonists, process for their preparation, and their use. | |
ZA200107716B (en) | Disodium salts, monohydrates and ethanol solvates. | |
TR200001102T2 (tr) | İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları. | |
ZA979670B (en) | Piperazino derivatives as neurokinin antagonists. | |
ZA964621B (en) | 2-substituted benzimidazole derivatives. | |
AU697041B2 (en) | Mannich base derivatives, and the production and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |